Navigation Links
AtheroGenics Reports ARISE Trial Results for AGI-1067

Full Study Results to Be Presented at the American College of Cardiology's Scientific Session

WIRE) -- 03/19/2007 -- AtheroGenics, Inc. (NASDAQ: AGIX) today announced that its ARISE Phase III clinical study of its lead drug candidate, AGI-1067, did not show a difference from placebo in its composite primary endpoint; however, it did achieve a number of other important predefined endpoints. These endpoints included a reduction in the composite of "hard" atherosclerotic clinical endpoints, composed of cardiovascular death, myocardial infarction (heart attack) and stroke, as well as an improvement in several key diabetes parameters, including glycemic control.

A full description of the ARISE study results will be presented by the ARISE principal investigators, Jean-Claude Tardif, M.D., Director of Research; Professor of Medicine, Montreal Heart Institute; and Marc Pfeffer, M.D., Ph.D., Professor of Medicine, Harvard Medical School; Senior Physician in Cardiology at Brigham and Women's Hospital, at the Late Breaking Clinical Trials session (Room Hall A) at the American College of Cardiology (ACC) Scientific Session in New Orleans on Tuesday, March 27 at 9:35 a.m. CDT.

While the company is disappointed that the composite primary endpoint was not met, it is encouraged by the positive results demonstrated in a number of disease states. As a result of the review of this data, the company has determined that the further development of AGI-1067 is important and the company currently intends to continue to pursue opportunities for development. The company will continue to review the data of the clinical study to prepare for discussions with the FDA to evaluate development paths forward for the drug.

A preliminary analysis of the safety data indicated th
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: AtheroGenics Reports ARISE Trial Results for AGI
(Date:11/28/2008)... Germany, November 28 German biote...hip in specialized HIV monitoring and,AIDS patien...g countries. In,the year 2008, 2.5 million patien...bust and highly affordable "CyFlow" system, suppor...th HIV/AIDS. Due to introduction of the,Partec in...
(Date:11/26/2008)...nn., Nov. 26 Children w...significantly increased risk of developing mental ...of a Mayo Clinic study published this month in Pe...ademy of Pediatrics. , , The retrospective ... with strabismus (misaligned eyes) and compared th...
(Date:11/25/2008)...ness can improve recovery , , Audio and Web...able on the Mayo Clinic News Blog. Please see the ... ROCHESTER, Minn., Nov. 25 /PRNewswire-USNewswire...e patients don,t think they,re having a stroke -- ...heir condition worsens. The findings appear in the...
(Date:11/25/2008)...NCISCO, Calif., Nov. 25 Proteolix,...of novel therapeutics that target,protein degrada...oday,announced that data from two ongoing Phase 2...ma will be presented at the upcoming 50th Annual M...). Carfilzomib is the first in a new class,of sp...
Breaking Medicine Technology:German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2Eye Divergence in Children Triples Risk of Mental Illness 2Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Homeland Security awards 2 grants to Rutgers for nuclear threat detection 422 1Homeland Security awards 2 grants to Rutgers for nuclear threat detection 422 2Homeland Security awards 2 grants to Rutgers for nuclear threat detection 422 3Fund Manager Joins Board of GSI Securitization Inc 1368 1Fund Manager Joins Board of GSI Securitization Inc 1368 2Billians HealthDATA GM Speaking on Dreamforce 07 Panel 1363 1Billians HealthDATA GM Speaking on Dreamforce 07 Panel 1363 2CryoLife Signs Distribution Agreement for Inclusion of BioGlue 28R 29 Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes 614 1CryoLife Signs Distribution Agreement for Inclusion of BioGlue 28R 29 Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes 614 2CryoLife Signs Distribution Agreement for Inclusion of BioGlue 28R 29 Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes 614 3
...g therapeutic cancer vaccine,trials have yet to sh... immune system to shrink tumors -- yet patients wh...nger and respond,better to subsequent treatment. I...journal of the American Association for Cancer,Res...hers asks a,fundamental question: are we looking a...
...)--Jul 5, 2007 - Australian,biotechnology company ...apricitabine,s controlled, double blinded phase wh...ase IIb trial.,Patients have now progressed into t...) and will continue to receive 800mg,apricitabine ...e.,The Company expects to release results from the...
Other Medicine Technology:From Clinical Cancer Research: Rethinking Therapeutic Cancer,Vaccine Trials 2From Clinical Cancer Research: Rethinking Therapeutic Cancer,Vaccine Trials 3Avexa's Apricitabine Clinical Trial Update 2
(Date:12/2/2008)... NDA with FDA in Early to Mid-2009 , , WARR...velopers of PharmFilm(R) technology and a drug del... pharmaceutical products, and Strativa Pharmaceuti...rmaceutical Companies, Inc. (NYSE: PRX ), today ... bioequivalence studies for a thin film formulatio...
(Date:12/2/2008)...c. 2 With the bright lights, sweet...holidays may be an exciting time of year for any c..., especially with today,s tough economy. Whether ...ptying their wallets, or spending hours traveling ...elax, and even less time to be alone and romantic ...
(Date:12/2/2008)...Dec. 2 Aduromed Industri...ovider of medical waste treatment,systems, today ... on November,24, 2008 to protect the Company,s pr...nerized MedClean Systems that provide a turnkey so...zation and volume reduction. , The patent a...
(Date:12/2/2008).... 2 Mylan Inc. (NYSE: ... Mylan Pharmaceuticals Inc., have entered,into a ... Corp., Novartis,Corp. and Novartis International...sion of Novartis, Femara(R). , Mylan,s Vice...re very,pleased to have reached this agreement, w...
Breaking Medicine News(10 mins):Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 2Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 3Health News:Jennie Finch Shares how to Fire up the Romance Despite the Demands of the Holidays 2Health News:Jennie Finch Shares how to Fire up the Romance Despite the Demands of the Holidays 3Health News:Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution 2Health News:Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution 3Health News:Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity 2
... the risk of diabetes in the Indigenous population...ott, Pro-vice Chancellor of the Division of Health...ows that while clinical care of adults with diabet...ndigenous Australians are developing the disease. ...
... epidemic of diabetes in the US is out. Spending o.... According to a drug trend report released by th...ailed only cholesterol medications in total prescr...n 2006. An aging population and the alarming rise...
...disfiguring accident that nearly killed him, but h...s home on Andrews Air Force Base in Maryland. N...e, that is, because of his brand-new nose. In a s... over a year-long period that ended with removal o...
...al Boston) and colleagues have identified the canc... soft-tissue sarcoma of childhood. 'Identifying ...ved genetic programs underlying self-renewal in ER... into how to destroy these cell types in establish...
Other Medicine News:Health News:Spending on Diabetes Drugs Soars in US 2Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 2Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 3Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 4Health News:Pediatric Cancer Stem Cell Identified 2
Bard Coude-Tip Latex Urethral Catheter, Two Eyes (Tiemann Model)
Used for stone manipulation and removal in the urinary tract. Supplied sterile in peel-open packages. Intended for one-time use.
The Coude tip design facilitates negotiation of the prostatic urethra. It is available in a medium length olive Coude tip with a single drainage eye. The red latex construction provides added stiffne
BARDEX Red Rubber Urethral Catheter (Robinson Model)
Medicine Products: